{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T04:09:46Z","timestamp":1785816586873,"version":"3.56.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP24K11537"],"award-info":[{"award-number":["JP24K11537"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.clim.2025.110616","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:51:58Z","timestamp":1761810718000},"page":"110616","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Prognostic value of lymphocyte-to-monocyte ratio in relapsed\/refractory adult T-cell Leukemia\/lymphoma patients receiving mogamulizumab"],"prefix":"10.1016","volume":"282","author":[{"given":"Yutaka","family":"Shimazu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuro","family":"Kameda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Kitawaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Kamiunten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Sekine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouichi","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Toyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzo","family":"Ishizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akifumi","family":"Takaori-Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2025.110616_bb0005","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1007\/s11864-023-01111-1","article-title":"Treatment of adult T-cell Leukemia\/lymphoma: established paradigms and emerging directions","volume":"24","author":"Stuver","year":"2023","journal-title":"Curr. Treat. Options in Oncol."},{"key":"10.1016\/j.clim.2025.110616_bb0010","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1111\/cas.14658","article-title":"Prognosis of patients with adult T-cell leukemia\/lymphoma in Japan: a nationwide hospital-based study","volume":"111","author":"Imaizumi","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.clim.2025.110616_bb0015","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","article-title":"VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan clinical oncology group study JCOG9801","volume":"25","author":"Tsukasaki","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clim.2025.110616_bb0020","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/bjh.15950","article-title":"Possibility of a risk-adapted treatment strategy for untreated aggressive adult T-cell leukaemia-lymphoma (ATL) based on the ATL prognostic index: a supplementary analysis of the JCOG9801","volume":"186","author":"Toyoda","year":"2019","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.clim.2025.110616_bb0025","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1200\/JCO.2016.67.7732","article-title":"Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia\/lymphoma: ATLL-002","volume":"34","author":"Ishida","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clim.2025.110616_bb0030","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1111\/cas.15431","article-title":"Oral histone deacetylase inhibitor tucidinostat (HBI-8000) in patients with relapsed or refractory adult T-cell leukemia\/lymphoma: phase IIb results","volume":"113","author":"Utsunomiya","year":"2022","journal-title":"Cancer Sci."},{"key":"10.1016\/j.clim.2025.110616_bb0035","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood.2022016862","article-title":"An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia\/lymphoma","volume":"141","author":"Izutsu","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clim.2025.110616_bb0040","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clim.2025.110616_bb0045","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/bjh.13338","article-title":"Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study","volume":"169","author":"Ishida","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.clim.2025.110616_bb0050","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1200\/JCO.2011.38.2101","article-title":"Prognostic index for acute- and lymphoma-type adult T-cell leukemia\/lymphoma","volume":"30","author":"Katsuya","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clim.2025.110616_bb0055","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1001\/jamadermatol.2021.0877","article-title":"Clinical characterization of mogamulizumab-associated rash during treatment of mycosis fungoides or S\u00e9zary syndrome","volume":"157","author":"Hirotsu","year":"2021","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.clim.2025.110616_bb0060","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood-2018-02-835991","article-title":"CCR4 mutations associated with superior outcome of adult T-cell leukemia\/lymphoma under mogamulizumab treatment","volume":"132","author":"Sakamoto","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clim.2025.110616_bb0065","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1182\/bloodadvances.2020003053","article-title":"Mogamulizumab for adult T-cell leukemia-lymphoma: a multicenter prospective observational study","volume":"4","author":"Yonekura","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.clim.2025.110616_bb0070","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70114","article-title":"Exploratory analysis of practical predictive indices for the efficacy of mogamulizumab in patients with aggressive adult T-cell leukemia-lymphoma","author":"Shimazu","year":"2025","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.clim.2025.110616_bb0075","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/ejh.12863","article-title":"Effects of mogamulizumab in adult T-cell leukemia\/lymphoma in clinical practice","volume":"98","author":"Sekine","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.clim.2025.110616_bb0080","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/ejh.13565","article-title":"Higher average chemotherapy dose intensity improves prognosis in patients with aggressive adult T-cell leukemia\/lymphoma","volume":"106","author":"Sekine","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.clim.2025.110616_bb0085","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/biostatistics\/kxt059","article-title":"Concordance for prognostic models with competing risks","volume":"15","author":"Wolbers","year":"2014","journal-title":"Biostatistics"},{"key":"10.1016\/j.clim.2025.110616_bb0090","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1002\/sim.8570","article-title":"Graphical calibration curves and the integrated calibration index (ICI) for survival models","volume":"39","author":"Austin","year":"2020","journal-title":"Stat. Med."},{"key":"10.1016\/j.clim.2025.110616_bb0095","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.clim.2025.110616_bb0100","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1007\/s00262-023-03514-3","article-title":"Pretreatment blast-to-lymphocyte ratio as a prognostic marker for CD19\/CD3-bispecific T cell-engaging antibodies (blinatumomab) treatment against relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"72","author":"Shimazu","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.clim.2025.110616_bb0105","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.lungcan.2018.08.012","article-title":"Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer","volume":"124","author":"Sekine","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clim.2025.110616_bb0110","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-024-03711-8","article-title":"The lymphocyte\/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients","volume":"73","author":"Shimazu","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.clim.2025.110616_bb0115","doi-asserted-by":"crossref","first-page":"5159","DOI":"10.1038\/s41598-023-32426-6","article-title":"Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa\/lambda ratio or B2 microglobulin","volume":"13","author":"Shimazu","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.clim.2025.110616_bb0120","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.23935","article-title":"Distribution and reference interval establishment of neutral-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR) in Chinese healthy adults","volume":"35","author":"Wang","year":"2021","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.clim.2025.110616_bb0125","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-09-2697","article-title":"Defucosylated humanized aanti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia\/lymphoma","volume":"16","author":"Ishii","year":"2010","journal-title":"Clin. Cancer Res."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661625001913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661625001913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T06:12:23Z","timestamp":1766038343000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661625001913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":25,"alternative-id":["S1521661625001913"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2025.110616","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic value of lymphocyte-to-monocyte ratio in relapsed\/refractory adult T-cell Leukemia\/lymphoma patients receiving mogamulizumab","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2025.110616","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110616"}}